(Bloomberg) -- Dr. Reddy's Laboratories Ltd. will have to wait a little longer before it can start selling a generic version of Indivior Plc's Suboxone Film opioid addiction treatment, a U.S. appeals court ruled Tuesday.
The sales ban will remain in force to give Indivior time to challenge a Nov. 20 appeals court decision it lost. In that ruling, a split 2-1 panel of the U.S. Court of Appeals for the Federal Circuit said a trial judge was wrong to block Dr. Reddy's from selling a generic version of Suboxone while a patent-infringement suit is pending.
The Federal Circuit said Indivior has until Dec. 20 to file a petition for rehearing in the case, and no extensions will be granted. The court rejected a Dr. Reddy's request that would have allowed the company to go to market immediately.
To contact the reporter on this story: Susan Decker in Washington at sdecker1@bloomberg.net
To contact the editors responsible for this story: Jon Morgan at jmorgan97@bloomberg.net, Elizabeth Wasserman
©2018 Bloomberg L.P.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
